Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts

The introduction of HAART (highly‐active‐antiretroviral‐therapy) has resulted in extended survival of HIV positive patients. Conversely, due to the prolonged expectancy of life and the ageing of the HIV positive population, tumors are now one of the major cause of death, and among them hepatocellular carcinoma (HCC) has become a growing concern in these patients. Considering the potential anti‐tumoral effects of HIV protease inhibitors, we decided to evaluate the anti‐tumoral activity of Amprenavir on liver carcinoma and to evaluate its potential synergistic effects in combination with standard chemoterapic drugs, such as Doxorubicin. Our results indicate that Amprenavir had direct inhibitory effects on invasion of Huh‐7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation. Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin. Furthermore, Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti‐angiogenetic and overall anti‐tumor activities, independently by PI3K/AKT related pathways that at today is one of the more suggestive hypothesis to explain the anti‐tumor effects of the different protease inhibitors. In summary these findings suggest novel anti‐neoplastic action of Amprenavir on liver cancer showing the possibility of novel combination therapies. J. Cell. Physiol. 228: 640–645, 2013. © 2012 Wiley Periodicals, Inc.

[1]  L. Galicier,et al.  The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo , 2012, Haematologica.

[2]  G. Abou-Alfa,et al.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. , 2010, JAMA.

[3]  C. Watson,et al.  Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts , 2010, Breast Cancer Research.

[4]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[5]  E. Aitini,et al.  Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. , 2010, The oncologist.

[6]  J. Pineda,et al.  Low Rate of Adverse Hepatic Events Associated with Fosamprenavir/Ritonavir-Based Antiretroviral Regimens , 2008, HIV Clinical Trials.

[7]  Ian Frank,et al.  Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans , 2008, Cancer biology & therapy.

[8]  M. Falagas,et al.  Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. , 2008, Current HIV research.

[9]  Richard D Moore,et al.  Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals , 2008, AIDS.

[10]  E. Seminari,et al.  Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. , 2007, The Journal of antimicrobial chemotherapy.

[11]  K. Flaherty,et al.  HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. , 2007, Cancer research.

[12]  L. Kincaid.  Modern HAART decreases cancers in children with HIV. , 2007, The Lancet Oncology.

[13]  A. Maity,et al.  HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. , 2006, Neoplasia.

[14]  P. Monini,et al.  The use of HAART for biological tumour therapy. , 2006, Journal of HIV therapy.

[15]  U. Tirelli,et al.  Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. , 2006, Annals of Oncology.

[16]  E. Palescandolo,et al.  Evaluation of Antitumoral Properties of the Protease Inhibitor Indinavir in a Murine Model of Hepatocarcinoma , 2006, Clinical Cancer Research.

[17]  Bryan L. Roth,et al.  Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery , 2005, Nature Reviews Drug Discovery.

[18]  Rosemarie Mick,et al.  HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. , 2005, Cancer research.

[19]  Y. Ohtsuki,et al.  HIV‐1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling , 2005, Cancer science.

[20]  M. Riera,et al.  Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. , 2005, European journal of internal medicine.

[21]  Olivia Keiser,et al.  Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. , 2005, Journal of the National Cancer Institute.

[22]  N. Bräu.  Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. , 2005, Seminars in liver disease.

[23]  R. Bruno,et al.  Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome , 2004, AIDS.

[24]  Y. Ohtsuki,et al.  HIV-1 Protease Inhibitor, Ritonavir , 2004, Cancer Research.

[25]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[26]  H. Koeffler,et al.  HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. , 2004, Molecular cancer therapeutics.

[27]  T. Cheung.  AIDS-Related Cancer in the Era of Highly Active Antiretroviral Therapy (HAART): A Model of the Interplay of the Immune System, Virus, and Cancer.—“On the Offensive—The Trojan Horse is Being Destroyed”— Part A: Kaposi's Sarcoma , 2004 .

[28]  T. Cheung.  AIDS-Related Cancer in the Era of Highly Active Antiretroviral Therapy (HAART): A Model of the Interplay of the Immune System, Virus, and Cancer. “On the Offensive—The Trojan Horse is Being Destroyed”—Part B: Malignant Lymphoma , 2004, Cancer investigation.

[29]  P. Morlat,et al.  Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) , 2003, AIDS.

[30]  C. Galanos,et al.  Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. , 2002, Cancer research.

[31]  D. Noonan,et al.  The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells , 2002, Oncogene.

[32]  Frank Pajonk,et al.  The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. , 2002, Cancer research.

[33]  M. Falchi,et al.  HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma , 2002, Nature Medicine.

[34]  E. Daar,et al.  HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. , 2000, Blood.

[35]  S. Franceschi,et al.  Cancer risk among men with, or at risk of, HIV infection in southern Europe , 2000, AIDS.

[36]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.

[37]  S. Fawell,et al.  Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  L. Galicier,et al.  The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo , 2012 .